[UnitedHealthcare] said that the ability to secure "very competitive pricing" led to giving Eli Lilly & Co.'s Basaglar copycat insulin preferred status on its commercial formulary, while cutting Sanofi's Lantus out and downgrading Novo Nordisk AS's Levemir.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?